Cerus Corporation (CERS)
1.44
0.00 (0.00%)
At close: Mar 28, 2025, 11:50 AM
0.00% (1D)
| Bid | 1.03 |
| Market Cap | 266.61M |
| Revenue (ttm) | 180.32M |
| Net Income (ttm) | -20.92M |
| EPS (ttm) | -0.11 |
| PE Ratio (ttm) | -13.05 |
| Forward PE | -35.33 |
| Analyst | Buy |
| Ask | 1.84 |
| Volume | 329,176 |
| Avg. Volume (20D) | 1,518,756 |
| Open | 1.46 |
| Previous Close | 1.44 |
| Day's Range | 1.42 - 1.45 |
| 52-Week Range | 1.38 - 2.54 |
| Beta | 1.56 |
About CERS
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed t...
Industry Medical - Devices
Sector Healthcare
IPO Date Jan 31, 1997
Employees 614
Stock Exchange NASDAQ
Ticker Symbol CERS
Website https://www.cerus.com
Analyst Forecast
According to 2 analyst ratings, the average rating for CERS stock is "Buy." The 12-month stock price forecast is $3.5, which is an increase of 143.90% from the latest price.
Stock ForecastsNext Earnings Release
Cerus Corporation is scheduled to release its earnings on May 1, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
-8.72%
Cerus shares are trading lower after the company r...
Unlock content with
Pro Subscription
5 months ago
-9.44%
Cerus shares are trading lower after Stifel cut its price target on the stock from $6 to $3.
